Abstract: Sepsis is one of the diseases with high mortality in acute and critical diseases，and its early diagnosis and intervention can improve the occurrence of adverse endpoint events and reduce the mortality to a certain extent. The classical biomarkers of sepsis, procalcitonin (PCT) and Creactive protein (CRP) have certain limitations in early identification and prognosis risk assessment of sepsis. Presepsin sCD14ST, as a newly discovered biomarker for sepsis diagnosis, has a good application prospect in the early diagnosis, treatment, and prognosis of sepsis.